If I Started Retatrutide Today, Here’s EXACTLY What I’d Do!

#Retatrutide #GLP1 #WeightLoss #ObesityMedicine #metabolichealth Retatrutide is producing weight loss results we used to only see after bariatric surgery — but the medication is only half the story. In this video, Dr. Mohammed Paika (board-certified in internal medicine and obesity medicine) breaks down the five decisions he'd make before ever taking a first dose: how to find the right dose instead of chasing the highest one, why your heart rate and mood deserve the same attention as the scale, how to protect your muscle while the weight comes off, how to build a supplement plan instead of guessing, and why the medication should never be allowed to do all the work on its own.Important: as of this video, retatrutide is still investigational and not yet FDA approved. Eli Lilly has completed three positive Phase 3 trials and plans to file for approval in Q1 2027. Right now it's accessible only through clinical trials or a narrow compassionate-use program — this video is the plan to have ready before that changes.🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter📚 The Weight Equation & The Physician’s PhysiquePhysician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.https://www.drmohammedpaika.com/books👥 Metabolic Health Communityhttps://www.skool.com/metabolic-health-community-5316Timestamps 0:00 – Intro2:38 – Where Things Stand: Is Retatrutide FDA Approved?4:35 – Rule 1: Dosing Is Not a Competition10:37 – Rule 2: The Scale Doesn't See Everything (Heart + Mood)16:50 – Rule 3: Muscle Is Not Optional21:30 – Rule 4: Supplements Need a Strategy, Not a Guess24:26 – Rule 5: Don't Let the Medication Do All the Work28:15 – The Five Decisions That Actually Matter29:18 – What To Do NextReferencesTRIUMPH-1 phase 3 trial results (weight loss %, BMI outcomes, discontinuation rates) — https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trialTRIUMPH-1 trial summary and safety profile — https://www.hcplive.com/view/retatrutide-weight-loss-endpoints-phase-3-obesity-trialRetatrutide phase 2 data — mechanism and heart rate increase (~6.7 bpm), Doggrell, Expert Opinion on Investigational Drugs, 2023 — https://pubmed.ncbi.nlm.nih.gov/37947489/FDA Drug Safety Communication — removal of suicidal ideation/behavior warning from GLP-1 receptor agonist labels (January 2026) — https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glpLilly TRIUMPH-2 and TRIUMPH-3 phase 3 results and planned Q1 2027 BLA submission — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additionalRetatrutide access status, August 2026 — https://www.ajmc.com/view/lilly-expands-retatrutide-access-amid-doctor-pushbackLean body mass loss data (SURMOUNT-1, STEP-1) and 2025 joint medical-society advisory — https://www.healio.com/news/endocrinology/20251114/muscle-matters-the-challenge-of-preserving-lean-mass-during-obesity-treatmentFothergill et al., "Persistent metabolic adaptation 6 years after The Biggest Loser competition," Obesity, 2016 — https://onlinelibrary.wiley.com/doi/full/10.1002/oby.21538American Medical Association's 2013 classification of obesity as a chronic disease — https://abcnews.go.com/Health/american-medical-association-classifies-obesity-disease/story?id=19439304 and https://obesitymedicine.org/blog/ama-adopts-policy-recognize-obesity-disease/"GLP-1 personality" — patient-reported emotional blunting and researcher commentary — https://health.yahoo.com/your-body/weight-management/weight-loss/article/what-is-ozempic-personality-125300474.htmlProtein targets and resistance-training rationale — Dr. Paika's GLP-1 Masterclass, Chapters 7 & 13 (internal course material)⚕️ MEDICAL & EDUCATIONAL DISCLAIMERThis channel and its content are provided by Dr. Mohammed K. Paika, MD for general educational and informational purposes only. The information presented is not intended as medical advice and does not replace consultation with your personal physician or qualified healthcare professional. Viewing this content does not create a doctor-patient relationship between you and Dr. Paika. Dr. Paika and affiliated entities disclaim any liability for injuries, adverse effects, or damages resulting from use or application of information presented in this content.